Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
BUSINESS
JCR to Develop 2 Mucopolysaccharidosis Drugs Using BBB-Penetrating Technology
JCR Pharmaceuticals said on April 21 that it will develop two new drug candidates for the treatment of mucopolysaccharidosis (MPS), JR-443 and JR-446, leveraging its proprietary blood-brain barrier (BBB)-penetrating technology. JR-443 is a BBB-penetrating beta-glucuronidase for the treatment of Sly…
To read the full story
BUSINESS
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026





